Melisa Guven

About

Melisa Guven is a Principal at Monograph’s London office, where she leads investments in therapeutics and pharmaceutical services and partners closely with portfolio companies on strategy and operations. She is a board observer at Elevara Medicines, Maxion Therapeutics, and Prolynx, and has held operational roles in the former two companies. Before joining Monograph, Melisa was an Engagement Manager at L.E.K. Consulting, advising clients across the healthcare and life sciences sectors, and a fellow with the World Economic Forum’s Healthcare Industries Platform. She holds a PhD in Cancer Biology (DNA repair) from the Francis Crick Institute, an MSc in Immunology, and a BSc in Biochemistry from Imperial College London.

Source (opens in a new tab)